Literature DB >> 35337031

Molecular Epidemiology of SARS-CoV-2 in Tunisia (North Africa) through Several Successive Waves of COVID-19.

Anissa Chouikha1,2,3, Wasfi Fares1,2,3, Asma Laamari1, Sondes Haddad-Boubaker1,2,3, Zeineb Belaiba1,2,3, Kais Ghedira4, Wafa Kammoun Rebai5, Kaouther Ayouni1,2,3, Marwa Khedhiri1,2,3, Samar Ben Halima2, Henda Krichen2, Henda Touzi1,2,3, Imen Ben Dhifallah1,2,3, Fatma Z Guerfali6, Chiraz Atri6, Saifeddine Azouz7, Oussema Khamessi8, Monia Ardhaoui3,9, Mouna Safer10, Nissaf Ben Alaya10, Ikram Guizani3,9, Rym Kefi5, Mariem Gdoura1,2,3, Henda Triki1,2,3.   

Abstract

Documenting the circulation dynamics of SARS-CoV-2 variants in different regions of the world is crucial for monitoring virus transmission worldwide and contributing to global efforts towards combating the pandemic. Tunisia has experienced several waves of COVID-19 with a significant number of infections and deaths. The present study provides genetic information on the different lineages of SARS-CoV-2 that circulated in Tunisia over 17 months. Lineages were assigned for 1359 samples using whole-genome sequencing, partial S gene sequencing and variant-specific real-time RT-PCR tests. Forty-eight different lineages of SARS-CoV-2 were identified, including variants of concern (VOCs), variants of interest (VOIs) and variants under monitoring (VUMs), particularly Alpha, Beta, Delta, A.27, Zeta and Eta. The first wave, limited to imported and import-related cases, was characterized by a small number of positive samples and lineages. During the second wave, a large number of lineages were detected; the third wave was marked by the predominance of the Alpha VOC, and the fourth wave was characterized by the predominance of the Delta VOC. This study adds new genomic data to the global context of COVID-19, particularly from the North African region, and highlights the importance of the timely molecular characterization of circulating strains.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; Tunisia; molecular characterization; next-generation sequencing; partial sequencing; spike gene; variant of concern; variant of interest; variants

Mesh:

Year:  2022        PMID: 35337031      PMCID: PMC8956073          DOI: 10.3390/v14030624

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), was first detected in December 2019 in the city of Wuhan in Hubei Province of China, in a patient with acute pneumonia [1,2,3]. On 11 March 2020, the World Health Organization (WHO) characterized COVID-19 as a pandemic. As of 06 March 2022, more than 440 million confirmed cases and more than 6 million deaths have been reported worldwide [4]. The first whole-genome sequence of SARS-CoV-2 was published on 5 January 2020 [2], and since then, the analysis of viral sequences worldwide has been continuous, with more than 2.5 million complete genomes currently available in public databases, such as the GISAID platform [5]. Molecular analysis has shown significant genetic variability of the SARS-CoV-2 virus due to the accumulation of mutations over time. Most of these changes have little to no impact, but some mutations have an impact on viral properties and lead to an increase in virus transmissibility, more severe infection, a potential reduction in vaccine or immune effectiveness and/or escape from molecular diagnosis. Variants that have acquired at least one of these characteristics are named variants of concern (VOCs) and require special monitoring. In addition, other variants are classified as variants of interest (VOIs), variants under monitoring (VUMs) or variants under investigation (VUIs) [6,7,8]. By July 2021, four major variants of concern (VOCs) had been described that led to increased surveillance efforts worldwide [9]. The Alpha variant, B.1.1.7 lineage (20I/501Y.V1, VOC-202012/01), also known as the UK variant, has an unusually high number of mutations and is more transmissible than the wild-type virus [10]. The Beta variant, B.1.351 lineage (501.V2, 20H/501Y.V2, VOC-202012/02), first detected and reported in South Africa in early October 2020, shares several mutations with B.1.1.7 and reduces vaccine effectiveness to some extent [11,12]. The Gamma variant, P.1 lineage (20J/501Y.V3, VOC-202101/02), emerged in December 2020 in Brazil [13]; it has 10 mutations in the spike protein that may affect its ability to be recognized by antibodies [14,15]. The Delta variant (B.1.617.2, AY.1 and AY.2 VOC-21APR-02) was first described in India and then widely spread all over the world [11,12]. This variant has eight mutations in the spike protein and is characterized by increased transmissibility in comparison with the Alpha variant [11,12]. In November 2021, a new VOC designated the Omicron variant (B.1.1.529) was first described in Botswana and in South Africa. This new variant has rapidly spread all over the world and is presently the most frequently detected worldwide [16,17]. This variant exhibits a large number of mutations, among which more than 30 are in the spike protein. The substitution mutations Q493R, N501Y, S371L, S373P, S375F, Q498R and T478K in the spike protein are suggested to result in increased transmission due to a higher affinity for human angiotensin-converting enzyme 2 (ACE2). Moreover, an increased risk of reinfection is observed with this variant as compared to other VOCs [16,17]. Therefore, the molecular monitoring of circulating strains is crucial for the timely identification of the emergence of novel SARS-CoV-2 variants. In Tunisia, the first cases of COVID-19-positive patients were reported in early March 2020, all of which were imported cases. By June 2020, 1155 cases had been reported, which were imported or import-related: persons coming from foreign countries and testing positive at arrival to Tunisia or persons who had been in contact with imported cases detected through contact tracing. After drastic decisions were taken by the Tunisian government, such as global lockdown, early detection of imported and local cases, quarantining of confirmed/suspected cases and border closures, case numbers reached zero between 4 and 12 June 2020 [18]. The second wave started in July 2020 after the borders reopened and a notable relaxation in compliance with preventive measures by the general population. After a small decrease in disease incidence in February 2021, the country experienced a third wave of COVID-19 with the introduction of the Alpha variant in March 2021 and then fourth and fifth waves after the introduction of Delta and Omicron in May and December 2021, respectively. The aim of the present study is to provide genetic information on the different lineages of SARS-CoV-2 that circulated in Tunisia during a period of 17 months (March 2020–July 2021) covering different waves.

2. Materials and Methods

2.1. Sample Collection

This study is based on nasopharyngeal samples tested in the Laboratory of Clinical Virology of Pasteur Institute of Tunis, mandated to perform COVID-19 diagnosis by the Tunisian Ministry of Health (MoH) as part of the national program of surveillance of SARS-COV-2. From March 2020 to 31 July 2021, 125,456 nasopharyngeal swab samples were referred from public and private health institutions, of which 28,517 (22.7%) were confirmed SARS-CoV-2-positive by real-time RT-PCR. Variant detection and lineage characterization were performed on a randomly selected subset of samples (N = 1359) covering the whole 17-month period and representing the 24 governorates of Tunisia. Three different techniques were used for the timely determination of the lineages circulating: whole-genome sequencing, partial S gene sequencing and real-time RT-PCR. The methods used for SARS-CoV-2 lineage and sub-lineage determination by month of sample collection are shown in Supplementary Material S1.

2.2. Whole-Genome Sequencing

Whole-genome sequencing was performed for 601 specimens with Ct values less than 30 that were collected throughout the whole 17-month study period. Of the 601 specimens, 10 were sequenced using MinION technology, and n = 591 were sequenced using Illumina technology as follows: RNA was extracted from a 140 μL nasopharyngeal sample with the Qiamp viral RNA mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Genomes were generated by an amplicon-based approach using the United States Food and Drug Administration (US FDA)-approved Illumina COVIDSeq kit (San Diego, CA, USA) [19], a modified version of the ARTIC protocol. The extracted RNAs were reverse transcribed to single-strand cDNA using Superscript IV Reverse Transcriptase (Invitrogen™, Waltham, MA, USA) as per the manufacturer’s instructions. SARS-CoV-2 PCR with two specific primer pools combined with proven Illumina sequencing technology allowed us to obtain 98 tiled amplicons covering the whole genome. For each sample, PCR products were combined, and libraries were prepared using the Illumina-Nextera DNA UD Indexes as per the manufacturer’s instructions. Libraries were purified with AMPure XP magnetic beads (Beckman Coulter, Brea, CA, USA), and concentration was measured by Qubit dsDNA HS Assay kit (Thermo Fisher Scientific, Waltham, MA, USA). Library pool validation and mean fragment size were determined by Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA) as per the manufacturer’s instructions. The 400 bp library pool was diluted to 4 nM. Libraries were pooled, denatured, diluted to 1.4 pM and sequenced on a NextSeq550 instrument with a V2.5 High Output Cartridge 2 × 150 bp run kit (Illumina, San Diego, CA, USA). Raw sequence data were processed using fastqc version 0.11.9 for quality control (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (accessed on 30 August 2021). Low-quality reads and adapters were filtered using trimmomatic version 0.39 with a Phred quality score of 30 as the threshold.

2.3. Genome Assembly

For the sequences generated by ONT MinION technology (Oxford Nanopore Technology, Oxford, UK), the depth ranged between 564× and 2.263×, and coverage ranged between 22,776 and 29,126. A modified ARTIC network pipeline v1.0.0 was used to generate consensus genomes with a reference-based genome assembly pipeline and read length filtering against the Wuhan-Hu-1 (RefSeq accession: NC_045512.2), and variants were polished using nanopolish v0.13.2, medaka v0.11.5 and samtools 1.9. For the sequences generated using Illumina Technology, the genomes were assembled using the EDGE COVID-19 pipeline, which is based on the fully open-source EDGE Bioinformatics software [20]. FaQCs was used to control the quality of the reads [21]. Low-quality regions of reads were trimmed and filtered if the reads failed a quality threshold of 20 or minimum length of 50 bp. The reads that passed the QC process were then aligned to the original Wuhan-Hu-1 complete reference genome (RefSeq accession: NC_045512.2) using BWA-mem [22]. Various parameters were set to default values: (i) minimum depth coverage (5×) to support a variant site, (ii) alternate base threshold (0.5) to support an alternative for a change in the consensus base, (iii) indel threshold (0.5) to support an INDEL for a change in the consensus base and (iv) minimum mapping quality [23].

2.4. Variant Detection by Partial Sequencing of the S Gene

Amplification by standard PCR and partial sequencing using Sanger technology was used for 358 samples collected from February to July 2021, as described previously [24]. The 648-nucleotide-long S gene sequence encodes for the 477 to 693 amino acid residue region of the S protein. It includes key positions and allows the detection of the most important mutations characterizing most VOCs, VOIs and VUMs.

2.5. Variant Detection by Real-Time RT-PCR

The commercial kit SNPsig® real-time PCR SARS-CoV-2 mutation detection/allelic discrimination kit (Primerdesign Ltd., Southampton, UK), which allows the detection of the Alpha, Beta and Gamma variants, was used for 400 samples collected from March to June 2021, during the high-transmission period of the Alpha variant. The test is based on the search for the first step of the N501Y substitution, which is common to the Alpha, Beta and Gamma variants. Discrimination between the three variants is then performed for all samples harboring the N501Y substitution using primers and probes specific to each variant.

2.6. Clade and Lineage Assignment

The Fasta format of whole genome sequences was used for clade and lineage assignment using online tools: Nextclade [10] and Pangolin (version 3.1.16, lineages version 2021-11-25) [25].

2.7. Phylogenetic Analysis

Multisequence alignment was performed with MAFFT using default parameters (https://mafft.cbrc.jp/alignment/server/ (accessed on 10 March 2022)) [26]. The resulting alignment was used to build a maximum likelihood phylogenetic tree using IQ-TREE online web server using an automatic substitution model supported by 1000 bootstrap replicates (http://iqtree.cibiv.univie.ac.at/ (accessed on 10 March 2022)) [27]. The phylogenetic tree was then visualized using Figtree software (http://tree.bio.ed.ac.uk/software/figtree/ (accessed on 10 March 2022)). Bootstrap values less than 60 are not shown in the tree. A Nextclade tree was also constructed using the online tool (https://clades.nextstrain.org/ (accessed on 10 March 2022)). The tree was then downloaded in JSON format and visualized using the Auspice v2.34.0 online tool (https://auspice.us/ (accessed on 10 March 2022)).

3. Results

In the present study, lineages could be successfully assigned to the 1359 SARS-CoV-2 samples using one of the three described methods. Overall, between March 2020 and 31 July 2021, a very high viral diversity was observed, with the identification of 48 different lineages (Table 1). According to the Pangolin lineage classification, the overwhelming majority of lineages detected (97.8%) belonged to B clade, with the low circulation of A (1.8%) and P (0.4%) clades (https://pangolin.cog-uk.io/ (accessed on 10 March 2022)). According to the Nextclade classification [10], 14 different clades were detected in Tunisia: 19A, 19B, 20A-E, 20G-I, 21A, 21D, 21I and 21J. Figure 1 shows the phylogenetic tree built using the Nextclade online tool (https://clades.nextstrain.org/ (accessed on 10 March 2022)). Figure 2 shows the phylogenetic tree based on Pangolin lineage classification and Table 1 illustrates the correspondence between the WHO, Pangolin lineage and Nextclade assignments according to the months of sample collection.
Table 1

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage distribution in Tunisia from March 2020 to July 2021 according to month of sample collection. Variants of concern (VOCs) and variants of interest (VOIs) are shown in red and in blue, respectively.

Wave 1Wave 2Wave 3Begining of Wave 4
WHOGISAID CladeNextstrain CladeMethodolgyPango Lineage Mar-20Apr-20Jun-20Jul-20Aug-20Sep-20Oct-20Nov-20Dec-20Jan-21Feb-21Mar-21Apr-21May-21Jun-21Jul-21Total
WGS B.1.153 1 1 2
WGS B.1.1 * 1 4 5 6 1 5 2 1 1 26
20A WGS B.1.36.10 1 1
WGS B.1 * 12 9 2 1 7 4 4 13 1 12 5 7 8 7 92
WGS B.1.520 1 1
19A WGS B.4 3 3
20A WGS B.1.36 1 1
20A WGS B.1.398 1 1
20A WGS B.1.214 2 2
20B WGS B.1.1.50 6 1 7
20C WGS B.1.597 1 1 2
20D WGS B.1.1.1 1 1 2
20A WGS B.1.22 2 1 2 5
20C WGS B.1.428.2 2 2 6 3 2 1 16
20B WGS B.1.1.25 2 2
20B WGS B.1.1.198 1 2 1 1 1 6
20B WGS B.1.1.189 1 3 4
WGS B.1.1.354 1 1
20E WGS B.1.177 2 7 6 2 6 4 7 4 38
20A WGS B.1.160 3 15 15 3 11 13 26 1 1 88
WGS B.1.111 1 1 2
20A WGS B.1.389 1 1
WGS B.1.575 1 2 1 4
20A WGS B.1.473 1 1
20C WGS B.1.595 1 1
WGS B.1.623 1 1
20A WGS B.1.236 1 1 2
WGS B.1.535 1 1
20A WGS B.1.533 1 1 2
Alpha GRY 20I WGS B.1.1.7 1 25 79 11 6 1 713
PS/qRT-PCR 1 3 113 79 277 112 5
20A WGS B.1.416 1 1 2
WGS B * 1 1
20A WGS B.1.243 1 1
Zeta 20B WGS P.2 4 1 5
19B WGS A.27 8 6 3 23
PS 3 2 1
19B WGS A.23.1 1 1 2
WGS B.1.415.1 1 1
Eta G/484K.V3 21D WGS B.1.525 2 6 1 1 20
PS 3 5 2
20A WGS B.1.160.14 2 2
20A WGS B.1.160.28 2 2
Beta GH/501Y.V2 20H WGS B.1.351 1 2
PS 1
WGS B.1.1.178 1 1
G 20A/S:126A WGS B.1.620 2 1 3
20E WGS B.1.1.318 2 6 1 9
20G WGS B.1.2 2 2
Delta G/478K.V1 21A,21I,21J WGS B.1.617.2 4 84 16 253
PS 6 92 51
20C/S:80Y WGS B.1.367 1 1
WGS B.1.629 1 1
Total 15 18 6 7 20 21 43 49 10 36 46 197 193 313 310 74 1359

* Lineages without any sub-lineage assignment, such as B, B.1 and B.1.1, were observed in n = 1, n = 92 and n = 26 cases, respectively. This was due to the quality of sequences generated, which did not allow proper assignment to a sub-lineage. PS = partial sequencing in the S gene; qRT-PCR = real-time PCR; and WGS = whole-genome sequencing.

Figure 1

Phylogenetic tree built using Nextclade online software (https://clades.nextstrain.org/tree (accessed on 10 March 2022))) and visualized using Auspice online tool (https://auspice.us/ (accessed on 10 March 2022) based on n = 463 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases detected in Tunisia between March 2020 and July 2021. The circles represent the Tunisian sequences in comparison with published sequences from all over the world. Here, Nextclade lineages are broken down according to the indicated color code.

Figure 2

Phylogenetic tree built using IQ-tree and visualized by Figtree based on n = 601 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) whole genomes detected in Tunisia between March 2020 and July 2021. The triangles in red correspond to variant of concern (VOC) sequences, variant of interest (VOI) sequences are shown in blue, and other lineages that circulated in Tunisia during the study period are represented in gray. The numbers on branches represent the bootstrap support values.

Table 1 and Figure 2 and Figure 3 report the different SARS-CoV-2 lineages detected during the four different waves of the disease in Tunisia during the 17-month study period.
Figure 3

Emergence of variants of concern (VOCs) and variants of interest (VOIs) in Tunisia between March 2020 and July 2021. In the background, is the number of positive cases detected in Tunisia according to the statistics published in the World Health Organization (WHO) website [18].

The first wave ranged from March to June 2020 and was characterized by small numbers of circulating lineages (n = 7), namely, B.1.153; B.1.36, B.1.36.10; B.1.398, B.1.214, B.520 and B.4, corresponding to the 19A and 20A Nextclade classifications. The second wave ranged from July 2020 to January 2021; it was characterized by a higher genetic diversity with the circulation of at least 20 different lineages, namely: B.1.1.50, B.1.597, B.1.1.1, B.1.22, B.1.428.2, B.1.1.25, B.1.1.198, B.1.1.189, B.1.1.354, B.1.177, B.1.160, B.1.111, B.1.389, B.1.575, B.1.473, B.1.595, B.1.623, B.1.236, B.1.535, B.1.533 and B.1.416 (20A to 20E according to the Nextclade classification) (Table 1). The third wave ranged from February to May 2021 and was characterized by the emergence of variants of concern (VOCs) and variants of interest and/or under monitoring. Indeed, the A.27 lineage, considered at that time to be a variant of interest, was first detected in Tunisia in February 2021, and the last isolate was identified in April 2021 (Table 1). The A.27 lineage is recognized by the following substitutions in the S gene: L18F, L452R, N501Y, A653V, H655Y, D796Y and G1219V, and was first detected in the present study using partial S gene sequencing. Starting from March 2021, the Alpha B.1.1.7 (UK) VOC, defined by multiple spike protein mutations, namely, deletions at 69–70 and 144, N501Y, A570D, D614G, P681H, T716I, S982A and D1118H, displaced the previous A.27 lineages and rapidly became the predominant variant detected in the country. Another VOC, the Beta (B.1.351) variant, known by the following S protein mutations: K417N, E484K, N501Y, D614G and A701V, was also detected in two cases, one in April and one in May 2021 during the third wave. Wave 3 was also characterized by the detection of a few cases of the Zeta (P.2) variant, the alias of B.1.1.28.2, also known as the Brazilian lineage, as well as the Eta (B.1.525) variant, known by the E484K substitution of interest and the del69–70 deletion. Zeta and Eta were, at that time, assigned as VUMs (variants under monitoring) (Table 1, Figure 3). Other sporadic lineages were also detected during the third wave: B.1.533, B.1.416, A.23.1, B.1.243, B.1.415, B.1.160, B.1.1.178, B.1.620, B.1.1.318 and B.1.2 (Table 1). During the beginning of the fourth wave (June–July 2021), the overwhelming majority of detected lineages was the Delta B.1.617.2 variant, known by the following mutations in the S protein: L452R, T478K, D614G and P681R. The Delta VOC rapidly displaced the Alpha VOC, which circulated with very few cases together with Eta, B.1.367 and B.1.575 lineages (Table 1, Figure 2). It is also important to note that some lineages, such as B.1.177 and B.1.160, circulated for a long period covering waves 2 and 3, extending from September 2020 to April–May 2021.

4. Discussion

In this retrospective observational study, we describe the SARS-CoV-2 lineages that circulated in Tunisia for 17 months after its first introduction to the country in March 2020. Significant genetic diversity of SARS-CoV-2 was observed with the circulation of many SARS-CoV-2 lineages during four different waves that the country experienced up to July 2021. This could be explained by different virus importations. Several factors could favor the multiple introductions of these different viral lineages to Tunisia and their rapid spread. First, Tunisia, a small country with an area of 163,610 km2 and a population of approximately 12 million, has a strategic geographic location, which makes it a junction point between the Arab world, Africa and Europe. Furthermore, it is known for its history of economic and cultural transactions, particularly with European and neighboring countries. In addition, Tunisia was experiencing an economic and political crisis that prevented total lockdown for long periods, and the introduction of the anti-SARS-CoV-2 vaccine to the population was relatively late. The succession of the different waves observed in Tunisia is similar to the global picture of COVID-19 infection (https://covid19.who.int/ (accessed on 30 August 2021)). In addition, the same picture of the circulation of several viral lineages has been reported in several countries around the world, such as the Czech Republic, Cyprus, the UK, Russia, South Africa and countries from the Middle East and North Africa (MENA) region [28,29,30,31,32,33]. The exchange between countries has played a crucial role in the importation of new lineages and their rapid spread across countries. This phenomenon is characteristic of airborne viruses. Countries that have succeeded in stopping their transmission are those that have applied drastic measures, such as China and South Korea, or other countries that were able to contain the virus during the first phases of the pandemic with full containment, border closures and the minimization of any contact, even between non-infected people [34,35,36,37,38]. In Tunisia, the first wave began with the introduction of the virus in March 2020; the drastic decisions taken by the government have effectively controlled the pandemic with a very low rate of infected persons that reached zero cases in June 2020. During this first wave, full compliance with sanitary measures by the population and the adequate decisions taken by decision-makers made it possible to contain the disease. At that time, the number of patients was not significant, especially those with severe disease requiring resuscitation and oxygen beds. On 27 June 2020, it was decided to reopen the borders. Countries were classified into three different categories depending on their epidemiological situation, and passengers coming from countries with low endemicity (green zones) were not required to self-isolate. This led to the re-emergence of the virus since some people coming from green zones were positive and reintroduced the virus in the country. Moreover, the summer period was marked by the return of emigrants and summer festivities, together with non-compliance with sanitary measures by the general population. This led to the outbreak of a second wave of COVID-19 with local transmission and two peaks coinciding with the start of the school year in September/October and the festivities celebrating the New Year in December 2020/January 2021. After a small decrease in disease incidence in February 2021, the country experienced a third wave of COVID-19 with the introduction of the Alpha VOC and A.27 VOI. The A.27 lineage was first detected in February 2021 concomitantly with its widespread emergence in France, a country with which Tunisia has important cultural and economic exchanges. At that time, the A.27 lineage, also named the Henry Mondor variant, was considered to be a variant of interest or variant under monitoring since it caused many grouped cases in France and harbors mutations described in VOCs [39]. The A.27 lineage shares substitutions with VOCs such as L18F, L452R and N501Y, which have been suggested to result in immune escape and higher transmissibility [40]. Currently, the A.27 lineage is not considered a VOI (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (accessed on 16 March 2022). Thereafter, it was quickly displaced by the Alpha B.1.1.7 VOC. The Alpha VOC, first detected in the United Kingdom in late 2020, is defined by an N501Y amino acid substitution in the spike protein that increases its transmissibility. The Alpha VOC had become the dominant global variant by early 2021 [5,33,40,41]. In Tunisia, it was first detected in January 2021 and rapidly became the dominant lineage. During this third wave, real-time PCR testing detecting the three VOCs detected around the world at that time (Alpha, Beta and Gamma) was used and allowed rapid screening for this variant. Other variants that have raised interest at the international level were also detected in our series, including the Beta variant (B.1.351), also known as 20H or variant of concern 501Y.V2. Beta was first described in South Africa and reported by Tegally et al. [11], and it was then detected in several countries on all continents, with the highest period of transmission between October 2020 and September 2021. In our series, it was detected in two travelers upon their arrival to Tunisia in April and May 2021; its early detection and the timely decisions taken contained this variant, hampering its spread in the country. The A.23.1 lineage was also detected. This lineage emerged in September 2020 and has several mutations with potential biological concern, including the 681R substitution, although it has not been classified as a VOC or VOI [42]. It was reported in several countries: 18 in Europe, 12 in Asia and 16 in sub-Saharan Africa, the USA, Canada and Australia. To our knowledge, it is reported herein for the first time in North Africa. The Eta (B.1.525) and Zeta (P2 or B.1.1.28) variants were also detected. Moreover, other lineages circulated for long periods, such as B.1.160 and B.1.177, which took an important place in the lineage landscape circulating in Tunisia. These lineages circulated from September 2020 until mid-2021 without any impact on the overall epidemiological situation. B.1.160, known as 20A/EU2, is one of the main variants first reported in Europe [43]. The B.1.177 lineage, mostly detected in Europe, was first detected in early 2020 and is currently classified into more than 80 sub-lineages [42]. Further molecular characterization of a higher number of viruses will be of great interest to better characterize these two lineages. In May 2021, the Delta variant, characterized by L452R and P681H amino acid substitutions in the spike protein, was detected in the country and rapidly displaced the Alpha variant, becoming the dominant variant in June–July 2021. This VOC, first detected in India in early 2021, became the most frequently detected variant in many countries [5,44,45]. Indeed, it was demonstrated that the Delta variant emerged faster than the Alpha variant and dominated the variant landscape worldwide. In the present study, the emergence of the Delta variant defined the fourth wave of SARS-CoV-2 infection in the country and participated in the resurgence of SARS-CoV-2 cases. The circulation of the Delta variant coincided with high transmissibility and with a large number of severe disease cases. In fact, infection with the Delta variant is characterized by the generation of an average of 6 times more viral RNA copies per milliliter than Alpha infections [12]. In Tunisia, the detection of the Delta variant decreased from August to December 2021 (data not shown). The disease incidence increased again with the introduction of Omicron, which was first detected in early December and caused a new wave with a much higher transmission rate.

5. Conclusions

This study describes the Tunisian experience in the molecular surveillance of SARS-CoV2. The generated genomic data contribute to the enrichment of the globally published data on SARS-CoV-2 circulation, particularly in North Africa. It highlights the efforts that have been made for rapid and efficient detection of variants despite the main limitation of the unavailability of onsite NGS technology. Lineage and sub-lineage assignments were performed using multiple methods, including whole-genome sequencing, partial sequencing of the S gene and screening for VOCs by real-time PCR. Although partial sequencing and VOC detection by real-time PCR do not allow complete characterization of lineages and sub-lineages, they were of great help in promptly identifying the introduction of the main VOCs, especially Alpha and Delta. Our study also points to three important measures that should be considered to prevent the emergence of new waves and new virus(es) introduction(s): (1) continuous respect of strict prevention measures without becoming complacent; (2) timely identification of new variants via clear procedures of genomic surveillance and (3) the strengthening of vaccination by raising awareness in the general population.
  28 in total

1.  MAFFT multiple sequence alignment software version 7: improvements in performance and usability.

Authors:  Kazutaka Katoh; Daron M Standley
Journal:  Mol Biol Evol       Date:  2013-01-16       Impact factor: 16.240

2.  Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.

Authors:  Nuno R Faria; Thomas A Mellan; Charles Whittaker; Ingra M Claro; Darlan da S Candido; Swapnil Mishra; Oliver G Pybus; Seth Flaxman; Samir Bhatt; Ester C Sabino; Myuki A E Crispim; Flavia C S Sales; Iwona Hawryluk; John T McCrone; Ruben J G Hulswit; Lucas A M Franco; Mariana S Ramundo; Jaqueline G de Jesus; Pamela S Andrade; Thais M Coletti; Giulia M Ferreira; Camila A M Silva; Erika R Manuli; Rafael H M Pereira; Pedro S Peixoto; Moritz U G Kraemer; Nelson Gaburo; Cecilia da C Camilo; Henrique Hoeltgebaum; William M Souza; Esmenia C Rocha; Leandro M de Souza; Mariana C de Pinho; Leonardo J T Araujo; Frederico S V Malta; Aline B de Lima; Joice do P Silva; Danielle A G Zauli; Alessandro C de S Ferreira; Ricardo P Schnekenberg; Daniel J Laydon; Patrick G T Walker; Hannah M Schlüter; Ana L P Dos Santos; Maria S Vidal; Valentina S Del Caro; Rosinaldo M F Filho; Helem M Dos Santos; Renato S Aguiar; José L Proença-Modena; Bruce Nelson; James A Hay; Mélodie Monod; Xenia Miscouridou; Helen Coupland; Raphael Sonabend; Michaela Vollmer; Axel Gandy; Carlos A Prete; Vitor H Nascimento; Marc A Suchard; Thomas A Bowden; Sergei L K Pond; Chieh-Hsi Wu; Oliver Ratmann; Neil M Ferguson; Christopher Dye; Nick J Loman; Philippe Lemey; Andrew Rambaut; Nelson A Fraiji; Maria do P S S Carvalho
Journal:  Science       Date:  2021-04-14       Impact factor: 47.728

3.  EDGE COVID-19: A Web Platform to generate submission-ready genomes from SARS-CoV-2 sequencing efforts.

Authors:  Chien-Chi Lo; Migun Shakya; Ryan Connor; Karen Davenport; Mark Flynn; Adán Myers Y Gutiérrez; Bin Hu; Po-E Li; Elais Player Jackson; Yan Xu; Patrick S G Chain
Journal:  Bioinformatics       Date:  2022-03-24       Impact factor: 6.937

4.  Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK.

Authors:  Louis du Plessis; John T McCrone; Alexander E Zarebski; Verity Hill; Christopher Ruis; Moritz U G Kraemer; Andrew Rambaut; Oliver G Pybus; Bernardo Gutierrez; Jayna Raghwani; Jordan Ashworth; Rachel Colquhoun; Thomas R Connor; Nuno R Faria; Ben Jackson; Nicholas J Loman; Áine O'Toole; Samuel M Nicholls; Kris V Parag; Emily Scher; Tetyana I Vasylyeva; Erik M Volz; Alexander Watts; Isaac I Bogoch; Kamran Khan; David M Aanensen
Journal:  Science       Date:  2021-01-08       Impact factor: 47.728

5.  High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next-generation sequencing.

Authors:  Rahul C Bhoyar; Abhinav Jain; Paras Sehgal; Mohit Kumar Divakar; Disha Sharma; Mohamed Imran; Bani Jolly; Gyan Ranjan; Mercy Rophina; Sumit Sharma; Sanjay Siwach; Kavita Pandhare; Swayamprabha Sahoo; Maheswata Sahoo; Ananya Nayak; Jatindra Nath Mohanty; Jayashankar Das; Sudhir Bhandari; Sandeep K Mathur; Anshul Kumar; Rahul Sahlot; Pallavali Rojarani; Juturu Vijaya Lakshmi; Avileli Surekha; Pulala Chandra Sekhar; Shelly Mahajan; Shet Masih; Pawan Singh; Vipin Kumar; Blessy Jose; Vidur Mahajan; Vivek Gupta; Rakesh Gupta; Prabhakar Arumugam; Anjali Singh; Ananya Nandy; Ragavendran P V; Rakesh Mohan Jha; Anupama Kumari; Sheetal Gandotra; Vivek Rao; Mohammed Faruq; Sanjeev Kumar; Betsy Reshma G; Narendra Varma G; Shuvra Shekhar Roy; Antara Sengupta; Sabyasachi Chattopadhyay; Khushboo Singhal; Shalini Pradhan; Diksha Jha; Salwa Naushin; Saruchi Wadhwa; Nishu Tyagi; Mukta Poojary; Vinod Scaria; Sridhar Sivasubbu
Journal:  PLoS One       Date:  2021-02-17       Impact factor: 3.240

6.  Lessons drawn from China and South Korea for managing COVID-19 epidemic: Insights from a comparative modeling study.

Authors:  Biao Tang; Fan Xia; Nicola Luigi Bragazzi; Zachary McCarthy; Xia Wang; Sha He; Xiaodan Sun; Sanyi Tang; Yanni Xiao; Jianhong Wu
Journal:  ISA Trans       Date:  2021-12-28       Impact factor: 5.911

7.  Molecular Analysis of SARS-CoV-2 Genetic Lineages in Jordan: Tracking the Introduction and Spread of COVID-19 UK Variant of Concern at a Country Level.

Authors:  Malik Sallam; Azmi Mahafzah
Journal:  Pathogens       Date:  2021-03-05

8.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

9.  Transmission dynamics and successful control measures of SARS-CoV-2 in the mega-size city of Guangzhou, China.

Authors:  Hongjun Zhao; Zhoubin Zhang; Wenhui Lun; Zongqiu Chen; Xiaoxiao Lu; Jingrong Li; Fuman Qiu; Shunming Li; Chun Mao; Ying Lu; Jinbin Chen; Qing He; Jiachun Lu; Zhicong Yang
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

View more
  2 in total

1.  SARS-CoV2 RT-PCR assays: In vitro comparison of 4 WHO approved protocols on clinical specimens and its implications for real laboratory practice through variant emergence.

Authors:  Mariem Gdoura; Imen Abouda; Mehdi Mrad; Imen Ben Dhifallah; Zeineb Belaiba; Wasfi Fares; Anissa Chouikha; Maroua Khedhiri; Kaouther Layouni; Henda Touzi; Amel Sadraoui; Walid Hammemi; Zina Meddeb; Nahed Hogga; Sihem Ben Fadhel; Sondes Haddad-Boubaker; Henda Triki
Journal:  Virol J       Date:  2022-03-28       Impact factor: 4.099

2.  The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance.

Authors:  Houriiyah Tegally; Eduan Wilkinson; James E San; Matthew Cotten; Monika Moir; Bryan Tegomoh; Gerald Mboowa; Darren P Martin; Cheryl Baxter; Arnold W Lambisia; Amadou Diallo; Daniel G Amoako; Moussa M Diagne; Abay Sisay; Abdel-Rahman N Zekri; Abdou Salam Gueye; Abdoul K Sangare; Abdoul-Salam Ouedraogo; Abdourahmane Sow; Abdualmoniem O Musa; Abdul K Sesay; Abe G Abias; Adam I Elzagheid; Adamou Lagare; Adedotun-Sulaiman Kemi; Aden Elmi Abar; Adeniji A Johnson; Adeola Fowotade; Adeyemi O Oluwapelumi; Adrienne A Amuri; Agnes Juru; Ahmed Kandeil; Ahmed Mostafa; Ahmed Rebai; Ahmed Sayed; Akano Kazeem; Aladje Balde; Alan Christoffels; Alexander J Trotter; Allan Campbell; Alpha K Keita; Amadou Kone; Amal Bouzid; Amal Souissi; Ambrose Agweyu; Amel Naguib; Ana V Gutierrez; Anatole Nkeshimana; Andrew J Page; Anges Yadouleton; Anika Vinze; Anise N Happi; Anissa Chouikha; Arash Iranzadeh; Arisha Maharaj; Armel L Batchi-Bouyou; Arshad Ismail; Augustina A Sylverken; Augustine Goba; Ayoade Femi; Ayotunde E Sijuwola; Baba Marycelin; Babatunde L Salako; Bamidele S Oderinde; Bankole Bolajoko; Bassirou Diarra; Belinda L Herring; Benjamin Tsofa; Bernard Lekana-Douki; Bernard Mvula; Berthe-Marie Njanpop-Lafourcade; Blessing T Marondera; Bouh Abdi Khaireh; Bourema Kouriba; Bright Adu; Brigitte Pool; Bronwyn McInnis; Cara Brook; Carolyn Williamson; Cassien Nduwimana; Catherine Anscombe; Catherine B Pratt; Cathrine Scheepers; Chantal G Akoua-Koffi; Charles N Agoti; Chastel M Mapanguy; Cheikh Loucoubar; Chika K Onwuamah; Chikwe Ihekweazu; Christian N Malaka; Christophe Peyrefitte; Chukwa Grace; Chukwuma E Omoruyi; Clotaire D Rafaï; Collins M Morang'a; Cyril Erameh; Daniel B Lule; Daniel J Bridges; Daniel Mukadi-Bamuleka; Danny Park; David A Rasmussen; David Baker; David J Nokes; Deogratius Ssemwanga; Derek Tshiabuila; Dominic S Y Amuzu; Dominique Goedhals; Donald S Grant; Donwilliams O Omuoyo; Dorcas Maruapula; Dorcas W Wanjohi; Ebenezer Foster-Nyarko; Eddy K Lusamaki; Edgar Simulundu; Edidah M Ong'era; Edith N Ngabana; Edward O Abworo; Edward Otieno; Edwin Shumba; Edwine Barasa; El Bara Ahmed; Elhadi A Ahmed; Emmanuel Lokilo; Enatha Mukantwari; Eromon Philomena; Essia Belarbi; Etienne Simon-Loriere; Etilé A Anoh; Eusebio Manuel; Fabian Leendertz; Fahn M Taweh; Fares Wasfi; Fatma Abdelmoula; Faustinos T Takawira; Fawzi Derrar; Fehintola V Ajogbasile; Florette Treurnicht; Folarin Onikepe; Francine Ntoumi; Francisca M Muyembe; Frank E Z Ragomzingba; Fred A Dratibi; Fred-Akintunwa Iyanu; Gabriel K Mbunsu; Gaetan Thilliez; Gemma L Kay; George O Akpede; Gert U van Zyl; Gordon A Awandare; Grace S Kpeli; Grit Schubert; Gugu P Maphalala; Hafaliana C Ranaivoson; Hannah E Omunakwe; Harris Onywera; Haruka Abe; Hela Karray; Hellen Nansumba; Henda Triki; Herve Albéric Adje Kadjo; Hesham Elgahzaly; Hlanai Gumbo; Hota Mathieu; Hugo Kavunga-Membo; Ibtihel Smeti; Idowu B Olawoye; Ifedayo M O Adetifa; Ikponmwosa Odia; Ilhem Boutiba Ben Boubaker; Iluoreh Ahmed Muhammad; Isaac Ssewanyana; Isatta Wurie; Iyaloo S Konstantinus; Jacqueline Wemboo Afiwa Halatoko; James Ayei; Janaki Sonoo; Jean-Claude C Makangara; Jean-Jacques M Tamfum; Jean-Michel Heraud; Jeffrey G Shaffer; Jennifer Giandhari; Jennifer Musyoki; Jerome Nkurunziza; Jessica N Uwanibe; Jinal N Bhiman; Jiro Yasuda; Joana Morais; Jocelyn Kiconco; John D Sandi; John Huddleston; John K Odoom; John M Morobe; John O Gyapong; John T Kayiwa; Johnson C Okolie; Joicymara S Xavier; Jones Gyamfi; Joseph F Wamala; Joseph H K Bonney; Joseph Nyandwi; Josie Everatt; Joweria Nakaseegu; Joyce M Ngoi; Joyce Namulondo; Judith U Oguzie; Julia C Andeko; Julius J Lutwama; Juma J H Mogga; Justin O'Grady; Katherine J Siddle; Kathleen Victoir; Kayode T Adeyemi; Kefentse A Tumedi; Kevin S Carvalho; Khadija Said Mohammed; Koussay Dellagi; Kunda G Musonda; Kwabena O Duedu; Lamia Fki-Berrajah; Lavanya Singh; Lenora M Kepler; Leon Biscornet; Leonardo de Oliveira Martins; Lucious Chabuka; Luicer Olubayo; Lul Deng Ojok; Lul Lojok Deng; Lynette I Ochola-Oyier; Lynn Tyers; Madisa Mine; Magalutcheemee Ramuth; Maha Mastouri; Mahmoud ElHefnawi; Maimouna Mbanne; Maitshwarelo I Matsheka; Malebogo Kebabonye; Mamadou Diop; Mambu Momoh; Maria da Luz Lima Mendonça; Marietjie Venter; Marietou F Paye; Martin Faye; Martin M Nyaga; Mathabo Mareka; Matoke-Muhia Damaris; Maureen W Mburu; Maximillian G Mpina; Michael Owusu; Michael R Wiley; Mirabeau Y Tatfeng; Mitoha Ondo'o Ayekaba; Mohamed Abouelhoda; Mohamed Amine Beloufa; Mohamed G Seadawy; Mohamed K Khalifa; Mooko Marethabile Matobo; Mouhamed Kane; Mounerou Salou; Mphaphi B Mbulawa; Mulenga Mwenda; Mushal Allam; My V T Phan; Nabil Abid; Nadine Rujeni; Nadir Abuzaid; Nalia Ismael; Nancy Elguindy; Ndeye Marieme Top; Ndongo Dia; Nédio Mabunda; Nei-Yuan Hsiao; Nelson Boricó Silochi; Ngiambudulu M Francisco; Ngonda Saasa; Nicholas Bbosa; Nickson Murunga; Nicksy Gumede; Nicole Wolter; Nikita Sitharam; Nnaemeka Ndodo; Nnennaya A Ajayi; Noël Tordo; Nokuzola Mbhele; Norosoa H Razanajatovo; Nosamiefan Iguosadolo; Nwando Mba; Ojide C Kingsley; Okogbenin Sylvanus; Oladiji Femi; Olubusuyi M Adewumi; Olumade Testimony; Olusola A Ogunsanya; Oluwatosin Fakayode; Onwe E Ogah; Ope-Ewe Oludayo; Ousmane Faye; Pamela Smith-Lawrence; Pascale Ondoa; Patrice Combe; Patricia Nabisubi; Patrick Semanda; Paul E Oluniyi; Paulo Arnaldo; Peter Kojo Quashie; Peter O Okokhere; Philip Bejon; Philippe Dussart; Phillip A Bester; Placide K Mbala; Pontiano Kaleebu; Priscilla Abechi; Rabeh El-Shesheny; Rageema Joseph; Ramy Karam Aziz; René G Essomba; Reuben Ayivor-Djanie; Richard Njouom; Richard O Phillips; Richmond Gorman; Robert A Kingsley; Rosa Maria D E S A Neto Rodrigues; Rosemary A Audu; Rosina A A Carr; Saba Gargouri; Saber Masmoudi; Sacha Bootsma; Safietou Sankhe; Sahra Isse Mohamed; Saibu Femi; Salma Mhalla; Salome Hosch; Samar Kamal Kassim; Samar Metha; Sameh Trabelsi; Sara Hassan Agwa; Sarah Wambui Mwangi; Seydou Doumbia; Sheila Makiala-Mandanda; Sherihane Aryeetey; Shymaa S Ahmed; Side Mohamed Ahmed; Siham Elhamoumi; Sikhulile Moyo; Silvia Lutucuta; Simani Gaseitsiwe; Simbirie Jalloh; Soa Fy Andriamandimby; Sobajo Oguntope; Solène Grayo; Sonia Lekana-Douki; Sophie Prosolek; Soumeya Ouangraoua; Stephanie van Wyk; Stephen F Schaffner; Stephen Kanyerezi; Steve Ahuka-Mundeke; Steven Rudder; Sureshnee Pillay; Susan Nabadda; Sylvie Behillil; Sylvie L Budiaki; Sylvie van der Werf; Tapfumanei Mashe; Thabo Mohale; Thanh Le-Viet; Thirumalaisamy P Velavan; Tobias Schindler; Tongai G Maponga; Trevor Bedford; Ugochukwu J Anyaneji; Ugwu Chinedu; Upasana Ramphal; Uwem E George; Vincent Enouf; Vishvanath Nene; Vivianne Gorova; Wael H Roshdy; Wasim Abdul Karim; William K Ampofo; Wolfgang Preiser; Wonderful T Choga; Yahaya Ali Ahmed; Yajna Ramphal; Yaw Bediako; Yeshnee Naidoo; Yvan Butera; Zaydah R de Laurent; Ahmed E O Ouma; Anne von Gottberg; George Githinji; Matshidiso Moeti; Oyewale Tomori; Pardis C Sabeti; Amadou A Sall; Samuel O Oyola; Yenew K Tebeje; Sofonias K Tessema; Tulio de Oliveira; Christian Happi; Richard Lessells; John Nkengasong
Journal:  Science       Date:  2022-10-07       Impact factor: 63.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.